ECSP034573A - Metodos para la produccion a gran escala de un tpa que se deriva de un adn recombinante o de moleculas de k2s - Google Patents
Metodos para la produccion a gran escala de un tpa que se deriva de un adn recombinante o de moleculas de k2sInfo
- Publication number
- ECSP034573A ECSP034573A EC2003004573A ECSP034573A ECSP034573A EC SP034573 A ECSP034573 A EC SP034573A EC 2003004573 A EC2003004573 A EC 2003004573A EC SP034573 A ECSP034573 A EC SP034573A EC SP034573 A ECSP034573 A EC SP034573A
- Authority
- EC
- Ecuador
- Prior art keywords
- tpa
- methods
- variant
- derived
- molecules
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108020004511 Recombinant DNA Proteins 0.000 title abstract 2
- 238000011031 large-scale manufacturing process Methods 0.000 title 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract 5
- 229960000187 tissue plasminogen activator Drugs 0.000 abstract 5
- 108020004414 DNA Proteins 0.000 abstract 4
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 3
- 108010079246 OMPA outer membrane proteins Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Abstract
La presente invención pertenece al sector de la trombolisis y de la producción de derivados del activador de plasminogeno tisular (tPA) en células procarióticas. El invento se refiere a métodos para la producción de un tPA que se deriva de un ADN recombinante, una variante de este o una molécula de K2S (Kringle 2 Serina) o una variante de esta en esta en células procarióticas, en el que dicho tPA o dicha K2S o dicha variante se segrega extracelularmente como una proteína activa y correctamente plegada, la célula procariótica contiene y expresa un vector que comprende el ADN que codifica dicho tPA o dicha K2S o dicha variante, unido operativamente con el ADN que codifica el péptido de señal OmpA. El invento se refiere además a derivados específicos de K2S obtenibles por dicho método. El invento se refiere además a dichas moléculas de ADN y al uso de dichas moléculas de ADN en dichos métodos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0027779.8A GB0027779D0 (en) | 2000-11-14 | 2000-11-14 | Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034573A true ECSP034573A (es) | 2003-05-26 |
Family
ID=9903153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004573A ECSP034573A (es) | 2000-11-14 | 2003-04-29 | Metodos para la produccion a gran escala de un tpa que se deriva de un adn recombinante o de moleculas de k2s |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1407030B1 (es) |
| JP (1) | JP2004520018A (es) |
| KR (1) | KR100856346B1 (es) |
| CN (1) | CN100567495C (es) |
| AR (1) | AR031334A1 (es) |
| AT (1) | ATE504652T1 (es) |
| AU (2) | AU2181502A (es) |
| BG (1) | BG66121B1 (es) |
| BR (1) | BR0115344A (es) |
| CA (1) | CA2428642C (es) |
| CZ (1) | CZ20031657A3 (es) |
| DE (1) | DE60144395D1 (es) |
| EA (1) | EA005163B1 (es) |
| EC (1) | ECSP034573A (es) |
| EE (1) | EE200300232A (es) |
| GB (1) | GB0027779D0 (es) |
| HR (1) | HRP20030377A2 (es) |
| HU (1) | HUP0301619A3 (es) |
| IL (2) | IL155568A0 (es) |
| MX (1) | MXPA03004161A (es) |
| MY (1) | MY129838A (es) |
| NO (1) | NO20032143L (es) |
| NZ (1) | NZ526280A (es) |
| PL (1) | PL206783B1 (es) |
| SK (1) | SK5792003A3 (es) |
| TW (1) | TWI292782B (es) |
| UA (1) | UA75102C2 (es) |
| UY (1) | UY27020A1 (es) |
| WO (1) | WO2002040650A2 (es) |
| YU (1) | YU36103A (es) |
| ZA (1) | ZA200303547B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087412B2 (en) | 2000-11-14 | 2006-08-08 | Boehringer Ingelheim International Gmbh | Methods for large scale protein production in prokaryotes |
| US6955910B2 (en) | 2000-11-14 | 2005-10-18 | Boehringer Ingelheim International Gmbh | Method for large scale production of recombinant DNA-derived TPA or K2S molecules |
| IL190184A0 (en) | 2008-03-16 | 2009-02-11 | Hadasit Med Res Service | tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6027888A (en) * | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| US20020061576A1 (en) * | 1997-05-28 | 2002-05-23 | Paul A. Moore | Tissue plasminogen activator-like protease |
| US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| EP1048732A1 (de) * | 1999-04-26 | 2000-11-02 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen |
| EP1077263A1 (de) * | 1999-07-29 | 2001-02-21 | F.Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen |
| GB0027782D0 (en) * | 2000-11-14 | 2000-12-27 | Boehringer Ingelheim Int | Methods fro large scale protein productio in prokaryotes |
-
2000
- 2000-11-14 GB GBGB0027779.8A patent/GB0027779D0/en not_active Ceased
-
2001
- 2001-07-11 UA UA2003065487A patent/UA75102C2/uk unknown
- 2001-11-07 SK SK579-2003A patent/SK5792003A3/sk unknown
- 2001-11-07 CA CA2428642A patent/CA2428642C/en not_active Expired - Fee Related
- 2001-11-07 EP EP01996596A patent/EP1407030B1/en not_active Expired - Lifetime
- 2001-11-07 CN CNB018188982A patent/CN100567495C/zh not_active Expired - Fee Related
- 2001-11-07 PL PL361881A patent/PL206783B1/pl not_active IP Right Cessation
- 2001-11-07 YU YU36103A patent/YU36103A/sh unknown
- 2001-11-07 DE DE60144395T patent/DE60144395D1/de not_active Expired - Lifetime
- 2001-11-07 NZ NZ526280A patent/NZ526280A/en unknown
- 2001-11-07 HU HU0301619A patent/HUP0301619A3/hu unknown
- 2001-11-07 EE EEP200300232A patent/EE200300232A/xx unknown
- 2001-11-07 MX MXPA03004161A patent/MXPA03004161A/es active IP Right Grant
- 2001-11-07 CZ CZ20031657A patent/CZ20031657A3/cs unknown
- 2001-11-07 BR BR0115344-7A patent/BR0115344A/pt not_active IP Right Cessation
- 2001-11-07 AT AT01996596T patent/ATE504652T1/de not_active IP Right Cessation
- 2001-11-07 EA EA200300502A patent/EA005163B1/ru not_active IP Right Cessation
- 2001-11-07 KR KR1020037006567A patent/KR100856346B1/ko not_active Expired - Fee Related
- 2001-11-07 HR HR20030377A patent/HRP20030377A2/hr not_active Application Discontinuation
- 2001-11-07 AU AU2181502A patent/AU2181502A/xx active Pending
- 2001-11-07 JP JP2002543647A patent/JP2004520018A/ja active Pending
- 2001-11-07 IL IL15556801A patent/IL155568A0/xx unknown
- 2001-11-07 AU AU2002221815A patent/AU2002221815B2/en not_active Ceased
- 2001-11-07 WO PCT/EP2001/012857 patent/WO2002040650A2/en not_active Ceased
- 2001-11-12 MY MYPI20015201A patent/MY129838A/en unknown
- 2001-11-12 UY UY27020A patent/UY27020A1/es not_active Application Discontinuation
- 2001-11-13 TW TW090128128A patent/TWI292782B/zh not_active IP Right Cessation
- 2001-11-14 AR ARP010105298A patent/AR031334A1/es unknown
-
2003
- 2003-04-24 IL IL155568A patent/IL155568A/en not_active IP Right Cessation
- 2003-04-29 EC EC2003004573A patent/ECSP034573A/es unknown
- 2003-05-08 BG BG107780A patent/BG66121B1/bg unknown
- 2003-05-08 ZA ZA200303547A patent/ZA200303547B/en unknown
- 2003-05-13 NO NO20032143A patent/NO20032143L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wagner et al. | Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. | |
| Collen et al. | Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo | |
| Heussen et al. | Purification of human tissue plasminogen activator with Erythrina trypsin inhibitor. | |
| Wang et al. | Deletion of Ile1 changes the mechanism of streptokinase: evidence for the molecular sexuality hypothesis | |
| CY1110546T1 (el) | Μεθοδοι για παραγωγη μεγαλης κλιμακας πεδιου kringle 2 συν πρωτεαση σερινης (k2s) του πλασμινογονου σε προκαρυωτες | |
| Liggieri et al. | Purification and Biochemical Characterization of Asclepain c I from the Latex of Asclepias curassavica L. | |
| Prusis et al. | Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases | |
| Wiederanders | The function of propeptide domains of cysteine proteinases | |
| ECSP034573A (es) | Metodos para la produccion a gran escala de un tpa que se deriva de un adn recombinante o de moleculas de k2s | |
| Renatus et al. | Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage | |
| Holland et al. | Proteins, exons and molecular evolution | |
| KR890000521A (ko) | 변형된 성장 인자 도메인을 갖는 조직 플라즈미노겐 활성제 동족체 | |
| AR046180A1 (es) | Metodo para producir proteinas gamma carboxiladas y uso terapeutico de las mismas | |
| Dahlmann et al. | Studies on the activation by ATP of the 26 S proteasome complex from rat skeletal muscle | |
| Calvete et al. | The disulfide bond pattern of catrocollastatin C, a disintegrin-like/cysteine-rich protein isolated from Crotalus atrox venom | |
| BR0313083A (pt) | moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas | |
| NO20053033L (no) | Anvendelse av caspase enzymer for modning av konstruerte rekombinante polypeptidfusjoner. | |
| Penzes et al. | Molecular mechanism of the interaction between activated factor XIII and its glutamine donor peptide substrate | |
| AR050561A1 (es) | Proteinas de fusion activadoras del plasminogeno como agentes tromboliticos. | |
| Busby et al. | 147 Expression of human plasminogen in baby hamster kidwey (BHK) cells | |
| Nicolaisen et al. | FVIIa derivatives obtained by autolytic and controlled cathepsin G mediated cleavage | |
| Light et al. | The amino-terminal sequence of the catalytic subunit of bovine enterokinase | |
| Smith et al. | Proteolytic fragmentation and H-NMR evdence for structurally independent domains in human uroiunase | |
| Åstedt et al. | Purification of urokinase by a beta-naphthamidine affinity column | |
| EP0381331A3 (en) | Gene sequences encoding modified residues situated in the protease domain of tpa |